An Integrated Tiered Service Delivery Model (ITSDM) Based on Local CD4 Testing Demands Can Improve Turn-Around Times and Save Costs whilst Ensuring Accessible and Scalable CD4 Services across a National Programme

Glencross, Deborah K.; Coetzee, Lindi M.; Cassim, Naseem
December 2014
PLoS ONE;Dec2014, Vol. 9 Issue 12, p1
Academic Journal
Background: The South African National Health Laboratory Service (NHLS) responded to HIV treatment initiatives with two-tiered CD4 laboratory services in 2004. Increasing programmatic burden, as more patients access anti-retroviral therapy (ART), has demanded extending CD4 services to meet increasing clinical needs. The aim of this study was to review existing services and develop a service-model that integrated laboratory-based and point-of-care testing (POCT), to extend national coverage, improve local turn-around/(TAT) and contain programmatic costs. Methods: NHLS Corporate Data Warehouse CD4 data, from 60–70 laboratories and 4756 referring health facilities was reviewed for referral laboratory workload, respective referring facility volumes and related TAT, from 2009–2012. Results: An integrated tiered service delivery model (ITSDM) is proposed. Tier-1/POCT delivers CD4 testing at single health-clinics providing ART in hard-to-reach areas (<5 samples/day). Laboratory-based testing is extended with Tier-2/POC-Hubs (processing ≤30–40 CD4 samples/day), consolidating POCT across 8–10 health-clinics with other HIV-related testing and Tier-3/‘community’ laboratories, serving ≤40 health-clinics, processing ≤150 samples/day. Existing Tier-4/‘regional’ laboratories serve ≤100 facilities and process <350 samples/day; Tier-5 are high-volume ‘metro’/centralized laboratories (>350–1500 tests/day, serving ≥200 health-clinics). Tier-6 provides national support for standardisation, harmonization and quality across the organization. Conclusion: The ITSDM offers improved local TAT by extending CD4 services into rural/remote areas with new Tier-3 or Tier-2/POC-Hub services installed in existing community laboratories, most with developed infrastructure. The advantage of lower laboratory CD4 costs and use of existing infrastructure enables subsidization of delivery of more expensive POC services, into hard-to-reach districts without reasonable access to a local CD4 laboratory. Full ITSDM implementation across 5 service tiers (as opposed to widespread implementation of POC testing to extend service) can facilitate sustainable ‘full service coverage’ across South Africa, and save>than R125 million in HIV/AIDS programmatic costs. ITSDM hierarchical parental-support also assures laboratory/POC management, equipment maintenance, quality control and on-going training between tiers.


Related Articles

  • Relationship between CD4+ Count and Non-AIDS Diseases in HIV Patients. Winslow, Dean L. // Infectious Disease Alert;Jun2008, Vol. 27 Issue 9, p101 

    EXACTLY 1397 ANTIRETROVIRAL (ARV) NAÏVE PATIENTS initiating ARVs, as part of a CPCRA-sponsored clinical trial (FIRST trial), were followed for a median of five years. Patients were randomized to one of three arms (NRTIs + PI, NRTIs + nnRTI, NRTIs + PI + nnRTI). CD4+ lymphocyte count, HIV RNA,...

  • Multidisciplinary, Inpatient Directly Observed Therapy for HIV-1–Infected Children and Adolescents Failing HAART: A Retrospective Study. Parsons, Genevieve N.; Siberry, George K.; Parsons, J. Kellogg; Christensen, James R.; Joyner, Mary L.; Lee, Stephanie L.; Kiefner, Carolyn M.; Hutton, Nancy // AIDS Patient Care & STDs;Apr2006, Vol. 20 Issue 4, p275 

    Children and adolescents with HIV-1 infection and elevated viral loads are at risk for disease progression. When outpatient adherence efforts fail to reduce viral loads, we have chosen to hospitalize patients for directly observed antiretroviral therapy. A retrospective chart review was...

  • Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study. De Salvador-Guillouët, F.; Sakarovitch, C.; Durant, J.; Risso, K.; Demonchy, E.; Roger, P. M.; Fontas, E. // PLoS ONE;10/20/2015, Vol. 10 Issue 10, p1 

    Background: As CD4/CD8 ratio inversion has been associated with non-AIDS morbidity and mortality, predictors of ratio normalization after cART need to be studied. Here, we aimed to investigate the association of antiretroviral regimens with CD4/CD8 ratio normalization within an observational...

  • The Impact of Monitoring HIV Patients Prior to Treatment in Resource-Poor Settings: Insights from Mathematical Modelling. Hallett, Timothy B; Gregson, Simon; Dube, Sabada; Garnett, Geoff P // PLoS Medicine;Mar2008, Vol. 5 Issue 3, pe53 

    Using a stochastic model based on data from Africa, Timothy Hallett and colleagues find that starting HIV treatment based on regular CD4 monitoring, rather than on symptoms, would substantially increase survival.

  • The Immunological Response after the Initiation of the Second Line Anti-Retroviral Therapy (ART) in HIV Patients. PILLAI, KEERTHI; RAMAPURAM, JOHN T.; ACHAPPA, BASAVAPRABHU; MADI, DEEPAK; CHOWTA, MUKTA N.; SATISH RAO, B.; MAHALINGAM, SOUNDARYA; UNNIKRISHNAN, B. // Journal of Clinical & Diagnostic Research;Sep2012, Vol. 6 Issue 7, p1171 

    Introduction: The treatment with the second line ART is initiated when the first line therapy fails. There is less experience with the immunologic response for the second-line ART for adults. Hence, this study was done to find out the immunological response after the initiation of the second...

  • The Cost-Effectiveness of Monitoring Strategies for Antiretroviral Therapy of HIV Infected Patients in Resource-Limited Settings: Software Tool. Estill, Janne; Salazar-Vizcaya, Luisa; Blaser, Nello; Egger, Matthias; Keiser, Olivia // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Background: The cost-effectiveness of routine viral load (VL) monitoring of HIV-infected patients on antiretroviral therapy (ART) depends on various factors that differ between settings and across time. Low-cost point-of-care (POC) tests for VL are in development and may make routine VL...

  • What we might know when START's finished.  // Research Initiative/Treatment Action!;Autumn2008, Vol. 13 Issue 2, p25 

    The article offers information on the Strategies for Timing of Antiretroviral Treatment (START), a randomized trial for HIV-infected patients. It aims to determine whether patients should begin therapy while their CD4 T-cells are still above 500 cells mm3 or wait until the count falls to 350...

  • Long-Term CD4+ Cell Count in Response to Combination Antiretroviral Therapy. Luz, Paula M.; Grinsztejn, Beatriz; Velasque, Luciane; Pacheco, Antonio G.; Veloso, Valdilea G.; Moore, Richard D.; Struchiner, Claudio J. // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Objective: There is a continuous debate on how to adequately evaluate long-term CD4+ cell count in response to combination antiretroviral therapy (ART) among human immunodeficiency virus (HIV)-infected individuals. Our study evaluated the long-term CD4+ cell count response (up to ten years)...

  • Antiretroviral therapy, CD4, viral load, and disease stage in HIV patients in Saudi Arabia: a 2001-2013 cross-sectional study. Memish, Ziad A.; Al-Tawfiq, Jaffar A.; Filemban, Sanaa M.; Qutb, Sayed; Fodail, Abdullah; Ali, Batol; Darweeish, May // Journal of Infection in Developing Countries;Jul2015, Vol. 9 Issue 7, p765 

    Introduction: The incidence of HIV/AIDS is increasing worldwide and in the Middle East. In this study, we analyzed the use of antiretroviral therapy (ART), the patterns of CD4 and viral load (VL), and stage of presentation. Methodology: Laboratory variables, ART use, and CD4 count were obtained...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics